Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers

References

• Wood JM, Maibaum J, Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698–7051. Wood JM, Maibaum J, Rahuel J. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003;308:698–705
   PubMed Web of Science ®Google Scholar
• Nussberger J, Wuerzner G, Jensen C. et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1–82. Nussberger J, Wuerzner G, Jensen C. et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1–8
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012–183. Gradman AH, Schmieder RE, Lins RL. et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012–18
   PubMed Web of Science ®Google Scholar
• Oh BH, Mitchell J, Herron JR. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157–634. Oh BH, Mitchell J, Herron JR. et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157–63
   PubMed Web of Science ®Google Scholar
• Weir MR, Bush C, Anderson DR. et al. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264–775. Weir MR, Bush C, Anderson DR. et al. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264–77
   PubMed Web of Science ®Google Scholar
• Andersen K, Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589–996. Andersen K, Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589–99
   PubMed Web of Science ®Google Scholar
• Sica D, Gradman AH, Lederballe O. et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27 Suppl:121 P–7977. Sica D, Gradman AH, Lederballe O. et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur Heart J 2006;27 Suppl:121 P–797
   Google Scholar
• Schmieder RE, Philipp T, Guerediaga J. et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens 2007;9 Suppl A:A182 P–4368. Schmieder RE, Philipp T, Guerediaga J. et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens 2007;9 Suppl A:A182 P–436
   Google Scholar
• Dieterle W, Faigle JW, Montigel C. et al. Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. Eur J Clin Pharmacol 1977;11:367–759. Dieterle W, Faigle JW, Montigel C. et al. Biotransformation and pharmacokinetics of acenocoumarol (Sintrom) in man. Eur J Clin Pharmacol 1977;11:367–75
   PubMed Web of Science ®Google Scholar
• Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol 1986;30:619–2310. Thijssen HH, Janssen GM, Baars LG. Lack of effect of cimetidine on pharmacodynamics and kinetics of single oral doses of R- and S-acenocoumarol. Eur J Clin Pharmacol 1986;30:619–23
   PubMed Web of Science ®Google Scholar
• Meinertz T, Kasper W, Kahl C. et al. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 1978;5:187–811. Meinertz T, Kasper W, Kahl C. et al. Anticoagulant activity of the enantiomers of acenocoumarol. Br J Clin Pharmacol 1978;5:187–8
   PubMed Web of Science ®Google Scholar
• Godbillon J, Richard J, Gerardin A. et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981;12:621–912. Godbillon J, Richard J, Gerardin A. et al. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981;12:621–9
   PubMed Web of Science ®Google Scholar
• Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30:416–4413. Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30:416–44
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433–614. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433–6
   PubMed Web of Science ®Google Scholar
• Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227–4615. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44:1227–46
   PubMed Web of Science ®Google Scholar
• Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci 2007;29:671–516. Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci 2007;29:671–5
   PubMed Web of Science ®Google Scholar
• Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3–917. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found 1983;64:3–9
   PubMedGoogle Scholar
• Sunkara G, Bigler H, Wang Y. et al. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Curr Med Res Opin 2004;20:41–818. Sunkara G, Bigler H, Wang Y. et al. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. Curr Med Res Opin 2004;20:41–8
   PubMed Web of Science ®Google Scholar
• Azizi M, Webb R, Nussberger J. et al. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 2006;24:243–5619. Azizi M, Webb R, Nussberger J. et al. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 2006;24:243–56
   PubMed Web of Science ®Google Scholar
• Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000;28:1284–9020. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000;28:1284–90
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmcol Toxicol 2005;97 Suppl 1:23921. Vaidyanathan S. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res Pharmcol Toxicol 2005;97 Suppl 1:239
   Google Scholar
• Kroon C, de Boer A, Hoogkamer JF. et al. Detection of drug interactions with single dose acenocoumarol: new screening method?. Int J Clin Pharmacol Ther Toxicol 1990;28:355–6022. Kroon C, de Boer A, Hoogkamer JF. et al. Detection of drug interactions with single dose acenocoumarol: new screening method?. Int J Clin Pharmacol Ther Toxicol 1990;28:355–60
   PubMedGoogle Scholar
• Bonnabry P, Desmeules J, Rudaz S. et al. Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol 1996;41:525–3023. Bonnabry P, Desmeules J, Rudaz S. et al. Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol 1996;41:525–30
   PubMed Web of Science ®Google Scholar
• Yates RA, Wong J, Seiberling M. et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001;51:429–3524. Yates RA, Wong J, Seiberling M. et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol 2001;51:429–35
   PubMed Web of Science ®Google Scholar
• Rolan P, Terpstra IJ, Clarke C. et al. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. Br J Clin Pharmacol 2003;55:314–1625. Rolan P, Terpstra IJ, Clarke C. et al. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol. Br J Clin Pharmacol 2003;55:314–16
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jarugula V, Dieterich H-A. et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515–3126. Vaidyanathan S, Jarugula V, Dieterich H-A. et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515–31
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Vaidyanathan S. et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527–3527. Dieterle W, Corynen S, Vaidyanathan S. et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005;43:527–35
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Valencia J, Kemp C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343–5628. Vaidyanathan S, Valencia J, Kemp C. et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343–56
   PubMed Web of Science ®Google Scholar